Subject(s)
Scleroderma, Systemic , Humans , Scleroderma, Systemic/economics , Crowdsourcing/economics , Cost of Illness , Female , Middle Aged , Fund Raising/economics , MaleABSTRACT
This cohort study examines the association between methotrexate use and interstitial lung disease in patients with dermatomyositis.
Subject(s)
Dermatomyositis , Lung Diseases, Interstitial , Methotrexate , Humans , Dermatomyositis/drug therapy , Dermatomyositis/chemically induced , Dermatomyositis/diagnosis , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/drug therapy , Methotrexate/adverse effects , Methotrexate/administration & dosage , Female , Middle Aged , Male , Adult , Dermatologic Agents/adverse effects , Dermatologic Agents/administration & dosage , Risk Factors , AgedABSTRACT
This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiationassociated gene 5 (MDA5) dermatomyositis.
Subject(s)
Continuity of Patient Care , Dermatomyositis , Hospitalization , Interferon-Induced Helicase, IFIH1 , Humans , Dermatomyositis/immunology , Dermatomyositis/drug therapy , Dermatomyositis/therapy , Interferon-Induced Helicase, IFIH1/immunology , Hospitalization/statistics & numerical data , Female , Continuity of Patient Care/organization & administration , Male , Middle Aged , Adult , Autoantibodies/blood , Autoantibodies/immunologySubject(s)
Dermatitis , Population Health , Scleroderma, Localized , Adult , Humans , Scleroderma, Localized/epidemiology , Skin , ComorbidityABSTRACT
This cohort study characterizes the presentation, causes, treatment, and disease course of erythema nodosum, as well as identifies associations with chronicity and recurrence.
Subject(s)
Erythema Nodosum , Humans , Erythema Nodosum/diagnosis , Erythema Nodosum/complications , RecurrenceABSTRACT
Neonatal lupus erythematosus (NLE) is an autoimmune disease caused by the passive transfer of autoantibodies from mother to child during pregnancy. A rare complication of NLE is hemophagocytic lymphohistiocytosis (HLH), a potentially life-threatening hyperinflammatory state more commonly associated with other rheumatologic disorders. Herein, we describe a fatal case of NLE-associated HLH.
Subject(s)
Lupus Erythematosus, Systemic , Lymphohistiocytosis, Hemophagocytic , Infant, Newborn , Pregnancy , Child , Humans , Female , Lymphohistiocytosis, Hemophagocytic/diagnosis , Lymphohistiocytosis, Hemophagocytic/etiology , Infectious Disease Transmission, Vertical , Lupus Erythematosus, Systemic/complications , AutoantibodiesSubject(s)
Atrial Fibrillation , Cardiovascular Diseases , Dermatomyositis , Myocardial Infarction , Population Health , Stroke , Humans , Cross-Sectional Studies , Dermatomyositis/epidemiology , Dermatomyositis/complications , Comorbidity , Myocardial Infarction/epidemiology , Atrial Fibrillation/complications , Risk Factors , Stroke/epidemiology , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/complicationsABSTRACT
Keloids and hypertrophic scars negatively impact the quality of life for millions of people in the world. Unfortunately, though many thera-peutic approaches are used to treat scars, they are often limited in efficacy with high rates of recurrence. Lately, a better understanding of the immune dysregulation of several dermatologic conditions has led to the emergence of multiple cytokine-targeted therapies for numerous conditions. Several studies have implicated T helper 2 (Th2) immune dysregulation in the development of scars and keloids, with interleukins (IL)-4 and -13 identified as pro-fibrotic mediators. Dupilumab is an IL-4 receptor alpha antagonist that inhibits the ex-pression of both IL-4 and -13. Herein, we describe a 44-year-old woman who developed numerous disfiguring hypertrophic scars and keloids after suffering from a severe herpes zoster infection. Given the number of scars, intralesional corticosteroid injections were not feasible. Therefore, treatment with systemic dupilumab was initiated. Many scars flattened, several even developing a cigarette-paper-like texture due to rapid involution. The largest and most recalcitrant keloid was further treated with intralesional dupliumab injec-tions every 2 weeks with an even more dramatic improvement noted in 2 months. To our knowledge, this is the first report of treating multiple keloids and hypertrophic scars with both systemic and intralesional dupilumab. Dermatologists may want to consider treating keloids that cover a large area with systemic dupilumab, a therapy with an established, reassuring safety profile. The most recalcitrant areas may further benefit from concentrating dupilumab by intralesional delivery. J Drugs Dermatol. 2023;22(12):1220-1222. doi:10.36849/JDD.6385.
Subject(s)
Cicatrix, Hypertrophic , Keloid , Female , Humans , Adult , Keloid/pathology , Cicatrix, Hypertrophic/drug therapy , Quality of Life , Antibodies, Monoclonal, Humanized/therapeutic use , Injections, Intralesional , Treatment OutcomeABSTRACT
This case series evaluates hyaluronidase for oral microstomia in a cohort of patients with autoimmune sclerosing disease.
